Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROLONG-ATE: BAX 855 in Severe Hemophilia A
NCT01736475Phase 3Completed
- Sponsor
- Takeda
- Start
- Jan 2013
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, open-label trial of recombinant coagulation factor viii in hemophilia A (2 arms), sponsored by Takeda. Primary endpoint: Annualized Bleeding Rate at 9 months. Started Jan 2013; status: completed.
02
Drugs
recombinant coagulation factor viii
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT01736475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01736475.